What Could a New Drug Approval Mean for CLL Patients?

http://youtu.be/7g93KYJpmYE Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Dr. Wierda reviews the treatment’s indications, the potential side effects and shares his perspective on what the approval could mean for a broader group of patients in the future. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo